Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC

References

• Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJ, Slebos RJ. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996; 56:2224-8; PMID:8616876
   PubMed Web of Science ®Google Scholar
• Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, Marchionni L, Agrawal N, Ravi R, Jones S, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun 2015; 6:8258; PMID:26374070; http://dx.doi.org/10.1038/ncomms9258
   PubMed Web of Science ®Google Scholar
• Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15:3243-8; PMID:11751630; http://dx.doi.org/10.1101/gad.943001
   PubMed Web of Science ®Google Scholar
• Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410:1111-6; PMID:11323676; http://dx.doi.org/10.1038/35074129
   PubMed Web of Science ®Google Scholar
• Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther 2014; 13:2876-85; PMID:25281617; http://dx.doi.org/10.1158/1535-7163.MCT-14-0074
   PubMed Web of Science ®Google Scholar
• Marcus K, Mattos C. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects. Clin Cancer Res 2015; 21:1810-8; PMID:25878362; http://dx.doi.org/10.1158/1078-0432.CCR-14-2148
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ, Philips MR. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Clin Cancer Res 2015; 21:1819-27; PMID:25878363; http://dx.doi.org/10.1158/1078-0432.CCR-14-3214
   PubMed Web of Science ®Google Scholar
• Fields AP, Frederick LA, Regala RP. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Biochem Soc Trans 2007; 35:996-1000; PMID:17956262; http://dx.doi.org/10.1042/BST0350996
   PubMed Web of Science ®Google Scholar
• Fields AP, Regala RP. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res 2007; 55:487-97; PMID:17570678; http://dx.doi.org/10.1016/j.phrs.2007.04.015
   PubMed Web of Science ®Google Scholar
• Gustafson WC, Ray S, Jamieson L, Thompson EA, Brasier AR, Fields AP. Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter. J Biol Chem 2004; 279:9400-8; PMID:14670960; http://dx.doi.org/10.1074/jbc.M312840200.
   PubMed Web of Science ®Google Scholar
• Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M. Involvement of PKC-iota in glioma proliferation. Cell Prolif 2008; 41:122-35; PMID:18211289; http://dx.doi.org/10.1111/j.1365-2184.2007.00506.x
   PubMed Web of Science ®Google Scholar
• Paul A, Gunewardena S, Stecklein SR, Saha B, Parelkar N, Danley M, Rajendran G, Home P, Ray S, Jokar I, et al. PKClambda/iota signaling promotes triple-negative breast cancer growth and metastasis. Cell Death Differ 2014; 21:1469-81; PMID:24786829; http://dx.doi.org/10.1038/cdd.2014.62
   PubMed Web of Science ®Google Scholar
• Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM, Fields AP. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005; 65:8905-11; PMID:16204062; http://dx.doi.org/10.1158/0008-5472.CAN-05-2372
   PubMed Web of Science ®Google Scholar
• Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, Sier D, Anastasiadis P, Gatalica Z, Thompson EA, Fields AP. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004; 164:797-802; PMID:15024028; http://dx.doi.org/10.1083/jcb.200311011
   PubMed Web of Science ®Google Scholar
• Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR. Protein kinase Cι is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Research 2010; 70:2064-74; PMID:20179210; http://dx.doi.org/10.1158/0008-5472.CAN-09-2684
   PubMed Web of Science ®Google Scholar
• Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:12519-24; PMID:16116079; http://dx.doi.org/10.1073/pnas.0505641102
   PubMed Web of Science ®Google Scholar
• Weichert W, Gekeler V, Denkert C, Dietel M, Hauptmann S. Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol 2003; 23:633-9; PMID:12888898
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O'Brien-Jenkins A, Massobrio M, Roby KF, et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66:4627-35; PMID:16651413; http://dx.doi.org/10.1158/0008-5472.CAN-05-4527
   PubMed Web of Science ®Google Scholar
• Wang Y, Hill KS, Fields AP. Protein Kinase Ciota maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol Cancer Res 2013; 11(12):1624-35
   PubMed Web of Science ®Google Scholar
• Diaz-Meco MT, Lozano J, Municio MM, Berra E, Frutos S, Sanz L, Moscat J. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta. J Biol Chem 1994; 269:31706-10; PMID:7989344
   PubMed Web of Science ®Google Scholar
• Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, Fields AP. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res 2009; 69:7603-11; PMID:19738040; http://dx.doi.org/10.1158/0008-5472.CAN-09-2066
   PubMed Web of Science ®Google Scholar
• Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005; 280:31109-15; PMID:15994303; http://dx.doi.org/10.1074/jbc.M505402200
   PubMed Web of Science ®Google Scholar
• Frederick LA, Matthews JA, Jamieson L, Justilien V, Thompson EA, Radisky DC, Fields AP. Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6alpha-mediated lung cancer. Oncogene 2008; 27:4841-53; PMID:18427549; http://dx.doi.org/10.1038/onc.2008.119
   PubMed Web of Science ®Google Scholar
• Justilien V, Fields AP. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation. Oncogene 2009; 28:3597-607; PMID:19617897; http://dx.doi.org/10.1038/onc.2009.217
   PubMed Web of Science ®Google Scholar
• Justilien V, Jameison L, Der CJ, Rossman KL, Fields AP. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation. J Biol Chem 2011; 286:8149-57; PMID:21189248; http://dx.doi.org/10.1074/jbc.M110.196113
   PubMed Web of Science ®Google Scholar
• Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS ONE 2012; 7:e35040; PMID:22545096; http://dx.doi.org/10.1371/journal.pone.0035040
   PubMed Web of Science ®Google Scholar
• Regala RP, Thompson EA, Fields AP. Atypical protein kinase Cι expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Research 2008; 68:5888-95; PMID:18632643; http://dx.doi.org/10.1158/0008-5472.CAN-08-0438
   PubMed Web of Science ®Google Scholar
• Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 1999; 17:1097-100; PMID:10545916; http://dx.doi.org/10.1038/15079
   PubMed Web of Science ®Google Scholar
• Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277:49374-82; PMID:12381725; http://dx.doi.org/10.1074/jbc.M209236200
   PubMed Web of Science ®Google Scholar
• Shultz JC, Vu N, Shultz MD, Mba MU, Shapiro BA, Chalfant CE. The Proto-oncogene PKCiota regulates the alternative splicing of Bcl-x pre-mRNA. Mol Cancer Res 2012; 10:660-9; PMID:22522453; http://dx.doi.org/10.1158/1541-7786.MCR-11-0363
   PubMed Web of Science ®Google Scholar
• Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP, Wicha MS. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 2013; 19:1972-80; PMID:23444212; http://dx.doi.org/10.1158/1078-0432.CCR-12-0370
   PubMed Web of Science ®Google Scholar
• Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010; 70:9937-48; PMID:21118965; http://dx.doi.org/10.1158/0008-5472.CAN-10-0881
   PubMed Web of Science ®Google Scholar
• Zheng Y, de la Cruz CC, Sayles LC, Alleyne-Chin C, Vaka D, Knaak TD, Bigos M, Xu Y, Hoang CD, Shrager JB, et al. A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 2013; 24:59-74; PMID:23845442; http://dx.doi.org/10.1016/j.ccr.2013.05.021
   PubMed Web of Science ®Google Scholar
• Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2011; 2:e200; PMID:21881602
   PubMedGoogle Scholar
• Pine SR, Ryan BM, Varticovski L, Robles AI, Harris CC. Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2010; 107:2195-200; PMID:20080668; http://dx.doi.org/10.1073/pnas.0909390107
   PubMed Web of Science ®Google Scholar
• Campos-Parra AD, Zuloaga C, Manriquez ME, Aviles A, Borbolla-Escoboza J, Cardona A, Meneses A, Arrieta O. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol 2015; 38:33-40; PMID:23538866; http://dx.doi.org/10.1097/COC.0b013e318287bb23
   PubMed Web of Science ®Google Scholar
• Hallqvist A, Enlund F, Andersson C, Sjogren H, Hussein A, Holmberg E, Nyman J. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer Int 2012; 2012:587424; PMID:26316935; http://dx.doi.org/10.1155/2012/587424
   PubMedGoogle Scholar
• Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, Riely GJ. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013; 119:356-62; PMID:22810899; http://dx.doi.org/10.1002/cncr.27730
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488:522-6; PMID:22854781; http://dx.doi.org/10.1038/nature11287
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98:1777-85; PMID:17179479; http://dx.doi.org/10.1093/jnci/djj495
   PubMed Web of Science ®Google Scholar
• Ali SA, Justilien V, Jamieson L, Murray NR, Fields AP. Protein Kinase Ciota Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell 2016; 29:367-78; PMID:26977885; http://dx.doi.org/10.1016/j.ccell.2016.02.012
   PubMed Web of Science ®Google Scholar
• Regala RP, Justilien V, Walsh MP, Weems C, Khoor A, Murray NR, Fields AP. Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation. PLoS ONE 2011; 6:e26439; PMID:22022614; http://dx.doi.org/10.1371/journal.pone.0026439
   PubMedGoogle Scholar
• Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014; 25:139-51; PMID:24525231; http://dx.doi.org/10.1016/j.ccr.2014.01.008
   PubMed Web of Science ®Google Scholar
• Kjaer S, Linch M, Purkiss A, Kostelecky B, Knowles PP, Rosse C, Riou P, Soudy C, Kaye S, Patel B, et al. Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes. Biochem J 2013; 451:329-42; PMID:23418854; http://dx.doi.org/10.1042/BJ20121871
   PubMed Web of Science ®Google Scholar
• Pillai P, Desai S, Patel R, Sajan M, Farese R, Ostrov D, Acevedo-Duncan M. A novel PKC-iota inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. Int J Biochem Cell Biol 2011; 43:784-94; PMID:21315177; http://dx.doi.org/10.1016/j.biocel.2011.02.002
   PubMed Web of Science ®Google Scholar
• Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, Fields AP. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res 2006; 66:1767-74; PMID:16452237; http://dx.doi.org/10.1158/0008-5472.CAN-05-3405
   PubMed Web of Science ®Google Scholar
• Erdogan E, Lamark T, Stallings-Mann M, Lee J, Pellecchia M, Thompson EA, Johansen T, Fields AP. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota. J Biol Chem 2006; 281:28450-9; PMID:16861740; http://dx.doi.org/10.1074/jbc.M606054200
   PubMed Web of Science ®Google Scholar
• Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, Karlin N, Fields AP. A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients. Oncology 2015; 88:208-13; PMID:25502607; http://dx.doi.org/10.1159/000369257
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR. Phase I dose escalation study of the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs 2013; 24(10):1079-83; PMID:23962904
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6; PMID:20068163; http://dx.doi.org/10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar